The development of selective oral V2 receptor antagonists has led to confirmation of established concepts of the pathogenesis of hyponatremia and to new approaches to its treatment. V2 receptor antagonists are effective and promising agents. Their properties as specific pharmacologic tools will facilitate the treatment of the different types of hyponatremia because of the improved predictability of response, and improved control of fine tuning of responses, compared with what is achieved by current therapies. In addition, the quality of life of hyponatremic patients will improve because there will be less need for severe fluid restrictions. It is likely that these agents can be administered over prolonged periods of time.
Copyright 2001 by W.B. Saunders Company